Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?

Keyphrases

• Reperfusion 100%
• ST-elevation Myocardial Infarction (STEMI) 100%
• Antiplatelet 100%
• ST-segment Elevation MI 100%
• Clinical Outcomes 66%
• Ischemia-reperfusion Injury 66%
• No-reflow 66%
• Receptor Antagonist 33%
• Pathophysiology 33%
• Improved Outcomes 33%
• Myocardial Fibrosis 33%
• Adenosine Receptors 33%
• Novel Pathways 33%
• Aspirin 33%
• Oral Administration 33%
• Myocardial Ischemia-reperfusion Injury 33%
• Patency 33%
• Infarction 33%
• Acute Myocardial Infarction 33%
• Early Onset 33%
• Myocardial Infarct Size 33%
• In-hospital Mortality 33%
• Myocardial Ischemia Injury 33%
• Percutaneous Coronary Intervention 33%
• Adjunctive Therapy 33%
• Modern History 33%
• Dynamic Nature 33%
• Antiplatelet Agents 33%
• Incremental Improvement 33%
• Infarct 33%
• Coronary Thrombolysis 33%
• Inducible Ischemia 33%
• Antiplatelet Therapy 33%
• Time Rate 33%
• Microvascular Damage 33%
• Cardiomyocyte Death 33%
• Early Reperfusion Therapy 33%
• Antiplatelet Activity 33%
• Adverse Remodeling 33%
• P2Y12 33%
• Door-to-balloon Time 33%
• Epicardial Coronary Arteries 33%

Pharmacology, Toxicology and Pharmaceutical Science

• ST Segment Elevation Myocardial Infarction 100%
• Antiplatelet 100%
• Reperfusion Injury 40%
• Infarction 40%
• No Reflow Phenomenon 40%
• Injury 20%
• Pathophysiology 20%
• Pharmacotherapy 20%
• Heart Muscle Ischemia 20%
• Ischemia 20%
• Acetylsalicylic Acid 20%
• Heart Infarction 20%
• Adenosine Receptor 20%
• Acute Heart Infarction 20%
• Hospital Mortality 20%
• Heart Muscle Necrosis 20%
• Antithrombocytic Agent 20%